View More Recent Stories
-
Dermata Therapeutics, Inc (DRMA) Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
-
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
-
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
-
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
-
Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
-
Dermata Therapeutics, Inc (DRMA) Files for 5.87M Share Offering by Selling Stockholders
-
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
-
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
-
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
-
Dermata Therapeutics In (DRMA) PT Lowered to $6 at Maxim Group
-
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
-
Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
